Oncosting
OncoSTING: Innovating bladder cancer therapies by enhancing BCG immunotherapy with potent STING agonists.
Founded
2018OncoSTING: Innovating bladder cancer therapies by enhancing BCG immunotherapy with potent STING agonists.
Founded in Baltimore, OncoSTING is dedicated to revolutionizing bladder cancer treatment. The company's core mission is to enhance the efficacy of standard Bacillus Calmette-Guérin (BCG) immunotherapy by integrating it with long-lasting delivery of potent STING agonists. This innovative approach aims to improve patient outcomes by leveraging the dual benefits of BCG and STING agonists. OncoSTING focuses on developing these advanced therapies specifically for bladder cancer patients, addressing a critical need in oncology.
Notable affiliates include researchers from Johns Hopkins University, contributing significant expertise to the company's development efforts. OncoSTING has attracted attention and investment from key stakeholders in the biotech and medical communities, underscoring its potential impact. The company has achieved important milestones in preclinical studies, demonstrating the promise of its combined therapy approach. Overall, OncoSTING is poised to make a substantial impact on bladder cancer treatment, offering new hope for patients through its innovative therapeutic strategies.
Companies similar to Oncosting include Stingray Therapeutics, Neoantigenics, Stimit and Irazu Oncology.
Oncosting was founded in 2018.
Oncosting's headquarters is located in Baltimore, MD, US.
Oncosting's most recent funding round was for $256k (USD) in June 2022.
As of Jun 1, 2022, Oncosting has disclosed funding of $406k (USD). Undisclosed round amounts are excluded.
Oncosting has 7 employees as of Feb 4, 2024.
irazuoncology.com
